SEC Tracker
Get the app
BNGO · XBRL financial data

Bionano Genomics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BNGO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers9,31810,721*8,7697,7716,0738,163*6,4576,7337,3677,951*6,6878,171
Cost of goods and services sold6,5698,283*5,9455,18614,5194,746*3,5193,2563,9974,552*3,4353,857
Research and development13,78511,701*9,7796,8314,7173,474*2,3702,9312,8443,229*3,1392,988
Selling, general and administrative24,89615,690*19,53611,5579,46411,746*9,0338,3469,0648,706*8,0108,544
Operating income (loss)(113,212)(24,953)*(31,123)(17,018)(43,901)(11,941)*(8,465)(7,800)(8,538)(8,536)*(7,897)(7,218)
Interest income—year only———year only———year only——
Interest expense714,898*122—————————
Other income (expense)263,562*(1,239)363(697)(8,408)*5,080676(219)362*(619)(344)
Income tax expense (benefit)39(36)*(18)26241*7101435*107
Net income (loss)(112,566)(43,891)*(31,422)(16,224)(44,246)(20,125)*(3,102)(6,857)(8,503)(7,933)*(8,303)(7,423)
Earnings per share, basic‡ USD per share(192.81)—(35.93)(14.37)(31.14)—(1.15)(1.99)(1.59)—(0.76)(0.64)
Earnings per share, diluted‡ USD per share(192.81)—(35.93)(14.37)(31.14)—(1.15)(1.99)(1.59)—(0.76)(0.64)
Weighted average shares, basic‡ thousands of shares585—8811,1291,434—2,6943,4415,338—10,97911,546
Weighted average shares, diluted‡ thousands of shares585—8811,1291,434—2,6943,4415,338—10,97911,546
  • ‡ Per-share figures and share counts are adjusted for the 1-for-59.880239520958085 stock split (January 2025); filings made before it reported them unadjusted.
  • † Share count changed about 1/34 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 67x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (BNGO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents34,56817,94815,75910,4258,7949,1733,6253,5623,0652,9903,4253,730
Marketable securities29,01448,82312,5618,5163,16030214,60612,87618,51616,27910,9806,189
Accounts receivable8,6699,3198,3136,2555,3164,7523,3543,4934,5265,2004,1334,366
Inventory33,51427,60223,80223,14916,28113,27611,41710,3088,4247,8287,6887,015
Prepaid and other current assets5,8576,0194,9454,8894,3873,1412,7823,0985,3785,2034,8644,890
Total current assets104,537140,11885,61160,56846,98039,48944,92942,66248,80045,38638,97524,878
Property and equipment, net21,26623,34525,27924,86319,99519,21918,33917,26416,17214,84714,04013,017
Right-of-use asset6,1705,6334,8704,2212,8331,8041,1083,7723,4973,2173,0622,935
Goodwill00——————————
Total assets181,904214,404157,995129,36487,36276,67078,41476,01079,06273,58464,80447,591
Accounts payable15,36910,3849,8448,7348,7006,9626,5626,2445,9905,5905,0624,562
Accrued liabilities11,5528,08911,0285,5305,8835,6413,9373,4054,7065,4603,9963,456
Total current liabilities40,194100,02858,50637,17532,95037,34426,40824,17822,97722,94221,22810,039
Lease liability, non-current4,0853,5902,7552,2421,73014502,7042,5992,4892,5072,384
Total liabilities62,905118,24775,22449,02738,49441,29530,22630,63629,26329,16027,34115,985
Accumulated deficit(537,317)(581,208)(612,630)(628,854)(673,100)(693,225)(696,327)(703,184)(711,687)(719,620)(727,923)(735,346)
Total stockholders' equity118,99996,15782,77180,33748,86835,37548,18845,37449,79944,42437,46331,606
Total liabilities and equity181,904214,404157,995129,36487,36276,67078,41476,01079,06273,58464,80447,591
Common shares outstanding (cover page)‡ thousands of shares6499131,1171,4361,703503,3644,68110,17611,09211,47511,777
  • ‡ Per-share figures and share counts are adjusted for the 1-for-59.880239520958085 stock split (January 2025); filings made before it reported them unadjusted.
  • † Share count changed about 1/34 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 67x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (BNGO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024†Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(112,566)(43,891)*(31,422)(16,224)(44,246)(20,125)*(3,102)(6,857)(8,503)(7,933)*(8,303)(7,423)
Stock-based compensation3,992*3,372*3,0152,583*2,202*1,936*1,5871,080*941*926*670970*
Depreciation and amortization3,625*3,596*3,0072,988*5,629*2,398*2,4342,380*2,376*2,337*2,3102,296*
Net cash from operating activities(26,293)*(29,779)*(28,131)(20,978)*(13,309)*(6,504)*(2,764)(3,487)*(5,919)*(4,175)*(5,716)(4,670)*
Net cash from investing activities33,427*(55,373)*47,58628,631*(5,375)*2,997*(14,066)1,979*(4,669)*4,009*5,45713,681*
Proceeds from issuing common stock12,924*11,286*15,44512,157*10,110*6,721*13,3173,091*12,939*1,751*705620*
Proceeds from issuing equity13,000*11,300*15,4002,200*100*3,700*—3,100—1,800*700600*
Net cash from financing activities12,588*68,484*(21,618)(1,978)*6,021*3,890*10,8911,469*10,076*1,603*657(9,693)*
Net change in cash19,712*(16,620)*(2,189)5,674*(12,639)*379*(5,948)(63)*(497)*1,444*403(681)*
  • † Share count changed about 1/34 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 67x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Bionano Genomics3,7308,171(4,670)*11.8M2.1 quarters 10-QJun 30, 2026
Focus Universal1,600675(741)*702,7452.2 quarters 10-QJun 30, 2026
Precipio3,0757,021660*1.8M— 10-QJun 30, 2026
Harvard Bioscience6,50322,727325*4.6M— 10-QJun 30, 2026
Syntec Optics Holdings14,0478,274(299)*40.3M47.0 quarters 10-QJun 30, 2026
MultiSensor AI Holdings21,0051,695(2,392)*2.2M8.8 quarters 10-QJun 30, 2026
Radnostix1,1962,672(614)*529.2M2.0 quarters 10-QJun 30, 2026
Optex Systems Holdings6,1759,7292,323*7.0M— 10-QJun 28, 2026
Electro Sensors10,756not reported683.5M— 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.